Skip to content

Trial to evaluate tolerance and safety of a new pre-thickened sip feed in subjects in need of oral nutritional support.

Randomised controlled open label trial to evaluate tolerance and safety of a new pre-thickened energy dense sip feed in subjects in need of oral nutritional support.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21624
Enrollment
50
Registered
2009-01-28
Start date
2009-02-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

After randomisation, patients will receive either the pre-thickened sip feed or a standard sip feed thickened with a commercially available thickening powder for 28 days. Measurements of weight, stool

Sponsors

Danone Research B.V.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female adult at least 18 years of age; 2. Subject is prescribed oral nutritional support of at least 300 kcal/day of energy enriched sip feed; 3. In case of new users: MUST score 1 (medium risk), or 2 or more (high risk); 4. Subject requires oral nutritional support for at least 4 weeks; 5. Written informed consent from subject.

Exclusion criteria

Exclusion criteria: 1. Known inflammatory bowel diseases (e.g. Crohns disease); 2. Known lactose intolerance and not using lactase; 3. Known galactosemia; 4. Major hepatic or renal dysfunction; 5. Subject with an ileostomy or colostomy; 6. Strong dislike of the flavours to be tested; 7. Requirement for oral nutritional support other than (thickened) energy enriched sip feeds (e.g. high protein sip feeds, disease specific sip feeds); 8. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements; 9. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Design outcomes

Primary

MeasureTime frame
1. Stool frequency; 2. Incidence and intensity of gastrointestinal symptoms; 3. Safety parameters in blood.

Secondary

MeasureTime frame
Study product intake (compliance).

Contacts

Public ContactG. Wijhe, van

P.O. Box 7005

gerda.vanwijhe@danone.com+31 (0)317467957

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)